Mesenchymal stem cells (MSCs) and their exosome (MSCs-Exos) have been shown to be major therapeutic candidates in regenerative medicine due to their inherent capacity for modulating immune response, promoting angiogenesis, and repairing tissues. However, clinical application of MSCs and MSCs-Exos is hindered by various intrinsic barriers, such as poor survival of transplanted MSCs, quick systemic clearance of exosomes, uncontrolled release of therapeutic payloads, and loss of function in severe pathological situations, such as chronic wounds and fibrotic tissues. To overcome these limitations, recent advances have focused on the design of modern delivery systems to enhance the stability, bioavailability, and functionality of MSCs and MSCs-Exos. These platforms include responsive hydrogels, engineered nanoparticles, and multi responsive intelligent dressings that mirror protective microenvironments in general and provide controlled, long-term distribution of bioactive elements. This current review focuses on such innovative approaches that enhance regeneration results in strong preclinical models, maximize therapeutic delivery, and boost MSCs and exosome survival. Despite remarkable advancements, major obstacles still exist, such as guaranteeing biosafety, achieving scale production, and obtaining regulatory approvals. The combination of MSCs and MSCs-Exos therapies with intelligent, responsive biomaterials capable of providing antimicrobial function and active monitoring has the potential to revolutionize tissue regeneration and wound healing and make MSCs and MSCs-Exos invaluable resources in precision regenerative medicine of the future.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor graft function (PGF) after allo-SCT remain to be controversial issues which may affect the transplantation outcome. Relevant articles were searched in MEDLINE database (2000–2016) using keywords and phrases: donor lymphocyte infusions, allogeneic stem cells transplantation, relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitoring protocols and technical aspects of apheresis. Relapse of disease and PGF could be reduced via noting some main points such as choosing the suitable time and patient for donor lymphocyte infusion (DLI) and also determination of patients who ought to candidate for second allogeneic HSCT or for the use of stem cell boost. DLI and stem cell booster are promising treatment strategies noted in this review. Finally, this paper discusses indications and technical aspects of DLI and stem cell booster in hematological malignancies and emphasizes their therapeutic or pre-emptive potentials.
4 September 2026 in Polymers for Advanced Technologies
Background: Pulmonary fibrosis is a progressive and often fatal disease featuring the disruption of lung architecture by excessive extracellular matrix deposition. Main Body: Mesenchymal stem cells (MSCs) have strong immunomodulatory, anti‐inflammatory and regenerative capacities that enable them to restore lung function through the targeting of key fibrotic mechanisms. Their migration into sites of injury and interaction with immune and structural cells through cytokines and growth factors underlines their therapeutic value. Recently, exosomes derived from MSCs have emerged as a promising cell‐free treatment option capable of crossing biological barriers and delivering anti‐fibrotic molecules like miRNAs, siRNAs, and proteins directly to fibrotic tissues. These vesicles enhance therapeutic precision and safety compared with cell therapy. Despite challenges in standardization, large‐scale production, and heterogeneity among MSCs sources, ongoing advances in biotechnology and clinical trial design are rapidly bridging the gap between preclinical promise and clinical application. Conclusion: This present review discusses the pathogenesis and modelling of pulmonary fibrosis and underlines MSCs and exosome‐based regenerative strategies as an effective and transforming approach in the future therapy of pulmonary fibrosis.
23 October 2025 in Polymers for Advanced Technologies